Trade PTC Therapeutics Inc - PTCT CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.12 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023401% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001179% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.1 | ||||||||
| Currency | USD | ||||||||
| Margin | 50.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 46.36 |
| Open | 45.78 |
| 1-Year Change | 81.52% |
| Day's Range | 45.78 - 47.45 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 17, 2025 | 47.36 | 2.36 | 5.24% | 45.00 | 47.68 | 45.00 |
| Apr 16, 2025 | 46.36 | 0.73 | 1.60% | 45.63 | 46.49 | 44.57 |
| Apr 15, 2025 | 46.87 | 2.51 | 5.66% | 44.36 | 48.41 | 43.20 |
| Apr 14, 2025 | 44.99 | 1.53 | 3.52% | 43.46 | 45.66 | 42.80 |
| Apr 11, 2025 | 42.92 | 4.18 | 10.79% | 38.74 | 43.41 | 38.74 |
| Apr 10, 2025 | 40.25 | -0.42 | -1.03% | 40.67 | 41.34 | 38.61 |
| Apr 9, 2025 | 42.67 | 2.91 | 7.32% | 39.76 | 43.81 | 36.98 |
| Apr 8, 2025 | 39.76 | -4.30 | -9.76% | 44.06 | 44.45 | 38.79 |
| Apr 7, 2025 | 42.72 | 1.50 | 3.64% | 41.22 | 44.78 | 40.54 |
| Apr 4, 2025 | 43.10 | -2.30 | -5.07% | 45.40 | 45.91 | 42.90 |
| Apr 3, 2025 | 46.68 | 0.29 | 0.63% | 46.39 | 47.93 | 45.70 |
| Apr 2, 2025 | 48.32 | 3.17 | 7.02% | 45.15 | 48.67 | 45.15 |
| Apr 1, 2025 | 46.55 | -3.74 | -7.44% | 50.29 | 50.91 | 46.30 |
| Mar 31, 2025 | 50.89 | -1.68 | -3.20% | 52.57 | 52.57 | 45.04 |
| Mar 28, 2025 | 54.12 | 0.17 | 0.32% | 53.95 | 55.04 | 53.45 |
| Mar 27, 2025 | 54.90 | 0.93 | 1.72% | 53.97 | 55.90 | 53.96 |
| Mar 26, 2025 | 55.19 | -0.26 | -0.47% | 55.45 | 55.80 | 54.18 |
| Mar 25, 2025 | 56.19 | -0.25 | -0.44% | 56.44 | 56.79 | 55.45 |
| Mar 24, 2025 | 56.93 | -0.47 | -0.82% | 57.40 | 57.40 | 55.54 |
| Mar 21, 2025 | 57.00 | 1.23 | 2.21% | 55.77 | 57.20 | 55.36 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 20
- 100
- 500
- 1000
- 10000
PTC Therapeutics Company profile
About PTC Therapeutics, Inc.
PTC Therapeutics, Inc. is a science-driven global biopharmaceutical company. The Company is focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The Company's portfolio pipeline includes several commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focused on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The Company has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD). It has a pipeline of gene therapy product candidates for rare monogenic diseases that affect the central nervous system (CNS), including PTC-AADC for the treatment of Aromatic L-Amino Acid Decarboxylase (AADC).
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, PTC Therapeutics, Inc. revenues increased 41% to $538.6M. Net loss increased 20% to $523.9M. Revenues reflect United States segment increase of 59% to $297M, Non-US segment increase of 24% to $241.6M. Higher net loss reflects Non-GAAP research and development increase of 11% to $487.1M (expense), Interest expense, net - Balancing value increase of 52% to $85.1M (expense).
Equity composition
Common Stock $0.001 Par, Shares auth 125M., 22,206,190 shares issd,. Insiders Owns approx.68.93%
| Industry: | Bio Therapeutic Drugs |
100 Corporate Ct
SOUTH PLAINFIELD
NEW JERSEY 07080-2400
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com